MedTrace Logo

To Evaluate the Efficacy of Eleutherococcus Senticosus for Subjects Under Renal Dialysis

NCT03210519 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-09-16

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled, parallel comparison trial to evaluate the efficacy and safety of Eleutherococcus Senticosus taken orally by patients under regular dialysis. Eligible subjects with written consent were randomized into one of the two groups: A. Acanthopanax senticosus (30mg/vial); B. Placebo. After 2-4 weeks of run-in period, the study subjects were asked to take the investigational products orally for 90 days in order to evaluate the effects of oral Eleutherococcus Senticosus liquid on the markers of inflammation, anemia, and safety, and to compare the efficacy among oral Acanthopanax senticosus and placebo.

Conditions

  • Renal Dialysis

Interventions

DIETARY_SUPPLEMENT

Eleutherococcus senticosus

taken orally once/day for 90 days

OTHER

Placebo

taken orally once/day for 90 days

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Nae-Cherng Yang, Ph. D. · Chun Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2017-06-30
Completion
2017-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210519 on ClinicalTrials.gov